Even as global financial slowdown is forcing companies to retrench jobs, MSD Pharmaceuticals, a subsidiary of US-based Merck & Co, today said it will employ 1,500 people in the next two years to strengthen its sales and marketing network and become a leading company by 2015.
"We will be doubling our staff strength in India in next two years as part of our plans to consolidate our marketing network in the country, which will further help us achieve our aim of listing among first five pharma companies by 2015," MSD Pharmaceuticals Managing Director Naveen A Rao said.
At present, the company has a total staff strength of 700 in India.
With an objective of expanding its product portfolio in the country, MSD Pharmaceuticals also plans to launch wide range of vaccines and medicines every six months.
"We have plans to launch our product range including vaccine and medicine which are relevant to India," he said.
He said that the company would launch its vaccine for hepatitis-A, Chickenpox and rotavirus. In addition, it would also bring out medicines for cardiovascular disease, dyspledemia and asthma.
The company has about six products-- four medicines and two vaccine for therapeutic areas namely, critical care, cardiovascular and metabolic at present in the Indian market.
